Category Archives: Blog

Tweet by Michael Okun Drugs for myoclonus

Michael Okun ⁦‪@MichaelOkun‬⁩ Have a person with ‘myoclonus’ in your practice and want to know what drug to choose for treatment and more importantly, what drug(s) not to choose. Ask the master ⁦‪@MarkHallett007‬⁩ Avoid phenytoin, gabapentin and carbamazepine. ⁦‪@movedisorder‬⁩ #Aspenite pic.twitter.com/oSECWXSMJT 8/4/22, 11:29 AM Joseph Thornton

MGH. employees sent to app for MH care

Roy Perlis ⁦‪@royperlis‬⁩ My health system – which includes the #1 and #3 departments of psychiatry in the country, according to US News – has decided to outsource mental health care for our employees and their families to a for-profit touting apps and coaches to get us back on our feet. pic.twitter.com/n3X4b5Hgmx 8/4/22, 9:36 AMContinue reading “MGH. employees sent to app for MH care”

Tweet by UF Health Cancer

UF Health Cancer Center ⁦‪@UFHealthCancer‬⁩ Prediction models can be prone to data bias. In a new ⁦‪@BMJ_Open‬⁩ article, ⁦‪@UFHealthCancer‬⁩ member ⁦‪@MasahikoKim‬⁩ & colleagues propose a protocol to develop the first reporting guidelines on causal prediction models. buff.ly/3cQDpVL ⁦‪@UFPHHP‬⁩ #AI #AIatUF 8/3/22, 3:50 PM Joseph Thornton

Tweet by Donna Fick, PhD, RN, delirium cause dementia preventable.

D Donna Fick, PhD, RN, GCNS-BC, FGSA, FAAN ⁦‪@agilis‬⁩ Engaging, impactful and evidence based keynote at AAIC by ⁦‪@sharon_inouye‬⁩ on the connection of delirium and dementia. Delirium as a risk factor for dementia. We have things we can do now! ⁦‪@iDelirium_Aware‬⁩ ⁦‪@johnahartford‬⁩ ⁦‪@AlzGPA‬⁩ ⁦‪@AgeFriendlyCare‬⁩ pic.twitter.com/d9ENSy96oT 8/4/22, 7:26 AM Joseph Thornton

Tweet by Michael Okun on DX functional disorders

Michael Okun ⁦‪@MichaelOkun‬⁩ .⁦‪@AlbertoEspay‬⁩ using his ⁦‪@TheLancet‬⁩ paper as the foundation for an Aspen ‘master class’ in distinguishing functional (psychogenic) disorders. The basis of your exam should always consider… thelancet.com/article/S0140-… ⁦‪@movedisorder‬⁩ pic.twitter.com/LYbeKmilev 8/3/22, 9:59 AM Joseph Thornton

Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis | The BMJ

https://www.bmj.com/content/378/bmj-2021-067606 Joseph Thornton

Tweet by Michael “Mike” Albert, Graphics mode action GLP

Michael “Mike” Albert, MD ⁦‪@MichaelAlbertMD‬⁩ Just so we can be clear about GLP1 therapy. They reduce ad libitum energy intake via their activity on the nervous system. In the case of SEMA, ad libitum Ein is reduced by 24-35%, depending on the dose and cohort. This effect on appetite explains wt loss. doi.org/10.1016/j.molm… pic.twitter.com/FBbWvqtd0W 8/2/22,Continue reading “Tweet by Michael “Mike” Albert, Graphics mode action GLP”

Tweet by Michael Okun on depression subtypes and treatment.

Michael Okun ⁦‪@MichaelOkun‬⁩ Do you identify these three types of depression in Parkinson’s disease BEFORE you choose a treatment? ⁦‪@JenGoldmanMD‬⁩ ⁦‪@movedisorder‬⁩ bringing this to our attention. We frequently forget depression symptoms can fluctuate with medication cycle. pic.twitter.com/hxWVApbxI5 8/1/22, 12:27 PM Joseph Thornton